- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05204901
Using Magnetic Field Tracking to Confirm Nasogastric Tube Placement at Point of Care
Using Magnetic Field Tracking to Confirm Nasogastric Tube Placement at Point of Care, A Feasibility Study
Study Overview
Status
Conditions
Detailed Description
In order to address the clinical need for the localization of nasogastric tube (NGT) at point-of-care, Nanyang Technological University, Tan Tock Seng Hospital and Woodlands Health Campus co-developed the prototype of a medical device that consists of a guidewire attached to a gold-plated Neodymium magnet to be used with a T-shaped body-worn sensors connected to a laptop. The magnetic-tipped guidewire is compatible with 14Fr or larger Ryles tubes. The sensors are passive and are designed to fit on the patient's sternum beginning at the level of the second intercostal space or xiphisternum. These sensors can track the changes in magnetic flux density real-time as the magnetic-tipped guidewire is inserted into the lumen of an NGT. The tracking may be done during NGT insertion or before feeding if confirmation of its location is required. The changes in magnetic flux density will be used to determine the location of the magnet in relation to the sensors. The result of these computations will be displayed on the computer screen as a trajectory of the magnet's movement inside the NGT. At full insertion of the guidewire, the trajectory should correspond to the actual location of the NGT in the patient.
This device is currently not in use but the investigators have notified the Health Science Authority of Singapore for its use as a Clinical Research Material.
The investigators aim to recruit 12 adult patients from both gender (6 each) who would already have had NGT placement and confirmation of its position by CXR within 48 hours of NGT insertion. These patients may have a variety of body habitus and will be screened according to a detailed list of exclusion criteria that rules out a recent medical history of oesophageal or gastric surgery, cardiac stent, pacemaker, implantable defibrillator or ferromagnetic implants in the neck, thorax, abdomen, pelvis or spine.
The investigators plan to test the following hypotheses and safety parameters.
- Concordance of our tracking with the trajectory of the NGT seen on chest X-ray
- The vertical and horizontal range of tracking
- The ability to detect a leftward deviation from the midline inferior to the xiphisternum
- Test-retest reliability
- Adverse events related to the magnetic-tipped guidewire or the sensors
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Hao Li, MBBS, MCI
- Phone Number: 98242657
- Email: li_hao@ttsh.com.sg
Study Contact Backup
- Name: Kon Voi Tay, MBBS, FRCS
- Email: kon_voi_tay@whc.sg
Study Locations
-
-
-
Singapore, Singapore, 308433
- Tan Tock Seng Hospital
-
Contact:
- Kon Voi Tay, MBBS, FRCS
- Email: kon_voi_tay@whc.sg
-
Contact:
- Hao Li, MBBS, MMED, MCI
- Email: li_hao@ttsh.com.sg
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients from the general ward or the Otorhinolaryngology clinic of Tan Tock Seng Hospital who had an NGT inserted within the last 10 days and chest X-ray confirming its correct placement
- The NGT inserted is a Ryles tube size Fr 14 or 16
- COVID negative or not deemed to be infective as judged by the prevailing policies at the time of recruitment
- Age > or = 21 years
- BMI < 35
- Height < 1.9m
- Mentally competent for informed consent
Exclusion Criteria:
• Radiological:
- On chest X-ray, the length of the NGT distal to the gastroesophageal junction is less than 12cm, or the side-holes of the NGT can be visualized in the esophagus.
- The NGT is kinked within 10cm of its tip
- The chest X-ray is rotated such that the thorax is not oriented in the frontal plane
- The NGT cannot be visualized in the mediastinum
The second intercostal space cannot be visualized on chest X-ray
• Medically unstable:
- Heart rate >=100 or <60
- Systolic blood pressure >=160 or <100
- SpO2 <92% in patients with chronic lung disease and <95% in patients without chronic lung disease
Temperature >= 38 degrees Celsius
• Chest wall deformity:
Patients with pectus carinatum or excavatum, defined by physical examination
• Patients with the following implants
- Pacemaker
- Automatic cardioverter defibrillator
- Ferromagnetic coronary stents or heart valves
- Ferromagnetic implants of the cranium, face, spine, sternum or ribs
Ferromagnetic surgical clips or implants in the head, neck, thorax, abdomen or pelvis
• Following conditions within the last 30 days
- Upper gastrointestinal bleeding
- Oesophageal or gastric surgery
- Stroke
- Myocardial infarction
- Aortic dissection
Ruptured aortic aneurysm
- Allergy to neodymium, gold, epoxy or nitinol
- Not able to understand English, Chinese, Malay or Tamil
- Women whose last menstrual period commenced more than 4 weeks before recruitment unless they have a negative urinary or serum pregnancy test during their current admission.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Magnetic tracking
This is the only arm of the study.
All 12 participants will undergo the insertion of the magnetic-tipped guidewire into their nasogastric tube after its correct placement is confirmed by chest X-ray.
|
In each participant, the investigator will place sensors on two sites of the sternum and track the location of the magnet as it is inserted and withdrawn from the nasogastric tube in the patients.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Probability of visualising a leftward deviation of the magnetic tipped guide-wire inferior to the xiphisternum
Time Frame: 6 months
|
The investigators will measure the rate of visualisation of a left-ward deviation of the magnet below the plane of xiphisternum in participants whose nasogastric tube deviates in such a way on chest X-ray.
|
6 months
|
Difference in the distance between the magnet and the datum with that between the nasogastric tube on chest X-ray and the datum
Time Frame: 6 months
|
The investigators will compare difference in distance (measured in millimetres) between the path of the nasogastric tube seen on magnetic tracking with that seen on chest X-ray by comparing them against a vertical midline (datum) centred over the midpoint of the sternum.
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
test-retest variability
Time Frame: 6 months
|
The investigators will compare the distance between the magnet and the datum at the insertion of the guide-wire against that obtained at withdrawal in order to determine the variation in the accuracy of the tracking with repeated testing.
|
6 months
|
Adverse events related to the device
Time Frame: 6 months
|
The investigators will record the incidence of magnet dislodgement, breakage of the guidewire, pain during insertion and withdrawal of the device, dermatitis over the chest wall in reaction to the sensors and any other unexpected adverse events caused by the device.
|
6 months
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- DSRB 2021/00435
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Gastrointestinal Diseases
-
Umeå UniversityRecruitingFunctional Gastrointestinal DisorderSweden
-
The University of Texas Medical Branch, GalvestonCompletedGastrointestinal Disorders, Functional
-
Campus Bio-Medico UniversityRecruitingGastrointestinal Cancer | Gastrointestinal Hemorrhage | Gastrointestinal Lesions | Gastrointestinal Injury | Gastrointestinal Perforation | Gastrointestinal UlcerItaly
-
Chang Gung Memorial HospitalNew Bellus EnterprisesUnknownNeoplasm | Functional Gastrointestinal DisorderTaiwan
-
Dr Anne PayneUniversity of LondonUnknownFunctional Gastrointestinal Disorders in ChildrenUnited Kingdom
-
Massachusetts General HospitalEnrolling by invitationGastrointestinal Dysfunction | Gastrointestinal DiseaseUnited States
-
Jiangxi University of Traditional Chinese MedicineThe First Affiliated Hospital of Nanchang University; Second Affiliated Hospital... and other collaboratorsCompletedGastrointestinal DiseaseChina
-
Virginia Commonwealth UniversityRecruitingFunctional Gastrointestinal DisordersUnited States
-
Assiut UniversityNot yet recruitingFunctional Gastrointestinal Disorders
-
Massachusetts General HospitalMassachusetts Institute of TechnologyEnrolling by invitationFunctional Gastrointestinal DisordersUnited States